相关实验视频

Updated: Apr 29, 2026

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2

Published on: November 5, 2021

具有改善抗SARS-CoV-2功效的Fc工程抗体疗法

Rachel Yamin¹, Andrew T Jones¹, Hans-Heinrich Hoffmann²

¹Laboratory of Molecular Genetics and Immunology, The Rockefeller University, New York, NY, USA.

|September 21, 2021

概括

针对SARS-CoV-2的优化单克隆抗体在预防和治疗COVID-19方面表现出更强的疗效. 在动物模型中提高功效,降低所需剂量并证明安全性.

科学领域:

免疫学
病毒学
药物开发

背景情况:

单克隆抗体 (mAbs) 可以中和SARS-CoV-2,从而降低轻度至中度病例的住院风险.
目前的mAbs需要高剂量,在严重或住院的COVID-19患者中有效性有限.

研究的目的:

开发和评估具有优化Fc域的抗SARS-CoV-2 mAbs,以获得更高的预防和治疗效果.
研究Fcγ受体参与抗体介导抗病毒免疫的作用.

主要方法:

开发具有优化Fc域的工程抗SARS-CoV-2 mAbs.
在多种动物模型中对COVID-19进行评估,以评估预防和治疗疾病的有效性.
分析Fcγ受体参与及其对抗病毒免疫力的影响.

主要成果:

在动物模型中,设计的mAbs在预防和治疗COVID-19方面表现出卓越的功效.
选择性Fcγ受体激活提高了疗效,并显著降低了所需的抗体剂量.
没有表现出致病或增强疾病的作用.

结论:

具有优化 Fc 效应器功能的 Fc 工程单克隆抗体可以提高对 COVID-19 的临床疗效.
对于强大的抗体介导抗病毒免疫,Fcγ受体通路至关重要.
这些发现支持开发新一代COVID-19治疗抗体.

更多相关视频

Engineering Antiviral Agents via Surface Plasmon Resonance

Engineering Antiviral Agents via Surface Plasmon Resonance

Published on: June 14, 2022

Author Spotlight: Advancing Antiviral Strategies Through Novel Immunocapture and Mass Spectrometry Techniques

Author Spotlight: Advancing Antiviral Strategies Through Novel Immunocapture and Mass Spectrometry Techniques

Published on: January 12, 2024

相关概念视频

Hybridoma Technology

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...